Status:
COMPLETED
Study to Investigate the Health Benefits of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms
Lead Sponsor:
Liaquat University of Medical & Health Sciences
Conditions:
Long COVID
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants wi...
Detailed Description
Long COVID-19, characterized by persistent symptoms lasting weeks or months after the acute phase of SARS-CoV-2 infection, presents a significant challenge for healthcare systems and affected individu...
Eligibility Criteria
Inclusion
- Age: 18 to 75 years.
- History of confirmed COVID-19 infection at least 6 months prior to the enrollment.
- Persistent mild to moderate COVID-19 symptoms for at least 3 months post-acute infection.
- Diagnosis of Long COVID-19 based on WHO criteria.
- Symptom burden score of ≥25 at baseline (V0) on the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS).
- At least one symptom scoring between 1-7 on the C19-YRS.
- Stable medical condition: No recent hospitalization (past 3 months) due to acute illness.
- Willing and able to adhere to the study protocol, including follow-up visits, symptom reporting, and compliance with supplementation
Exclusion
- Hypersensitivity or allergy to quercetin, curcumin, or any component of the supplement (Nasafytol®).
- Severe, uncontrolled chronic illness (e.g., severe heart failure, chronic kidney disease requiring dialysis, severe liver disease).
- Regular use of quercetin or curcumin supplements within the last 3 months.
- Use of anticoagulants (e.g., warfarin, heparin, DOACs) due to potential anticoagulant effects of quercetin/curcumin.
- Acute illness at the time of screening.
- Pregnancy or breastfeeding.
- Use of immunosuppressive medications or corticosteroids within the past month.
- Significant psychiatric disorder that may interfere with study compliance.
Key Trial Info
Start Date :
July 22 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 14 2025
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06974058
Start Date
July 22 2025
End Date
December 14 2025
Last Update
December 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Liaquat University of Medical & Health Sciences (LUMHS)
Jamshoro, Sindh, Pakistan, 76090